Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × NSCLC × pembrolizumab × Clear all

Status

Unknown 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 60 Melanoma 41 Squamous Cell Carcinoma of Head and Neck 33 Neoplasms 22 Neoplasm Metastasis 21 Head and Neck Neoplasms 20 Breast Neoplasms 19 Colorectal Neoplasms 18 Carcinoma, Renal Cell 16 Triple Negative Breast Neoplasms 14 Carcinoma, Transitional Cell 13 Stomach Neoplasms 12 Ovarian Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Lung Neoplasms 10 Uterine Cervical Neoplasms 9 Pancreatic Neoplasms 9 Esophageal Neoplasms 9 Urinary Bladder Neoplasms 8 Small Cell Lung Carcinoma 7 Recurrence 7 Multiple Myeloma 7 Carcinoma, Hepatocellular 7 Endometrial Neoplasms 6 Carcinoma, Merkel Cell 6 Skin Neoplasms 5 Prostatic Neoplasms 5 Mesothelioma, Malignant 5 Mesothelioma 5 Lymphoma, Non-Hodgkin 5

Interventions

Pemetrexed 3 Carboplatin 3 HM781-36B 2 Gemcitabine 2 pembrolizumab 1 osimertinib 1 aumolertinib 1 aflutinib 1 Taxes 1 Paclitaxel 1 Erlotinib Hydrochloride 1 Clinical Trials, Phase I as Topic 1 Cisplatin 1 Bortezomib 1 BID protein, human 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04557007 2026-01-29

Oncomabs

Oslo University Hospital

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡